Trading in STENOCARE shares by closely related party to board member

HHTM ApS, a closely related party to STENOCARE board member Henrik Elbæk, reported purchases totaling 363,232 STENOCARE shares executed on Nasdaq First North Growth Market Denmark between Dec 17 and Dec 29, 2025, with an aggregated value of DKK 505,318. The initial notification filed under EU Market Abuse Regulation (Article 19) details per‑day volumes and average prices and confirms the transactions were purchases. STENOCARE is a Danish medical‑cannabis supplier, and while the insider‑level buying may attract investor attention, the disclosure is routine regulatory reporting and does not by itself alter company fundamentals.

Analysis

Market structure: The disclosed purchase (363,232 shares for DKK505k at DKK1.29–1.50 in Dec 2025) is a small but visible insider buy that likely benefits retail holders and the board member’s closely related party; it does not materially change supply/demand or pricing power in EU medical cannabis given STENOCARE’s niche EU‑GMP positioning and patented ASTRUM oil. Winners: existing small‑cap STENO shareholders (short‑term sentiment uptick) and specialist distributors if commercial roll‑outs speed up; Losers: short sellers with tight stops and highly leveraged cannabis growers exposed to North American regulatory risk. Cross‑asset impact is negligible — bonds, FX and commodities won’t move on a DKK0.5m trade, but options/OTC liquidity may widen spreads temporarily.

Risk assessment: Tail risks are regulatory (Danish/EU reimbursement reversal, tightened cultivation/import rules), product (ASTRUM bioavailability claims disputed) and funding (microcap cash burn) with low probability but >30% P&L impact if triggered. Immediate (days): minor price blip on disclosure; short‑term (weeks/months): sentiment drift if management follows up with further buys or commercial news; long‑term (12+ months): fundamentals hinge on contract wins, export approvals and gross margin scale. Hidden dependencies include concentrated supplier contracts and reimbursement pathways; catalysts to watch: Danish Medicines Agency rulings, first export license, quarterly cash runway updates within 30–90 days.

Trade implications: Direct play: establish a small tactical long in STENO (ticker STENO on NASDAQ First North) sized 1–2% of equity risk at prices ≤DKK1.60, target +50–100% in 6–12 months, hard stop −30% (e.g., sell if <DKK1.10). If derivatives/liquidity exist, prefer a 6‑9 month call spread (buy DKK1.20–sell DKK2.40) to cap premium; otherwise avoid shorting due to limited float and information asymmetry. Pair trade: long STENO 1% vs short 1% exposure to larger international cannabis growers (e.g., TLRY) to isolate EU‑regulatory upside. Rotate: reduce exposure to non‑EU‑GMP growers and reallocate up to 2% into compliant EU medical‑cannabis small caps.

Contrarian angles: Market will likely underreact — DKK0.5m of insider buying is symbolic not transformational; contrarian edge is that insiders buying at ~DKK1.3–1.5 suggests management sees valuation floor. Historical parallel: microcap biotech insider buys precede outperformance ~+40–60% over 6–12 months in ~30% of cases but with high variance; be prepared for lumpy moves and low liquidity. Unintended risk: insider buying can bait momentum flows that reverse sharply on any operational miss, so size positions conservatively and require follow‑on confirmation within 60–120 days.

Key Decisions for Investors

• Establish a tactical long position in STENO (STENO on Nasdaq First North) equal to 1–2% of equity risk if price ≤DKK1.60; set a profit target of +50–100% over 6–12 months and a hard stop at −30% (e.g., sell if price <DKK1.10).
• If liquid options exist, deploy a 6–9 month bull call spread (buy DKK1.20 call, sell DKK2.40 call) sized to equal 1% notional exposure to cap premium and time decay; otherwise use shares due to OTC options illiquidity.
• Execute a relative‑value pair: long STENO 1% vs short 1% exposure to large multi‑jurisdiction cannabis growers (e.g., TLRY) to harvest idiosyncratic EU regulatory upside while hedging sector risk.
• Reduce non‑EU‑GMP cannabis exposure by 1–3% and reallocate into EU‑compliant medical cannabis small caps; monitor Danish Medicines Agency decisions and the company cash‑runway statement within the next 30–90 days before scaling position further.